CONNECTING Healthcare EXPERTISE

THE CLINICIAN EXCHANGE is a virtual exchange designed to pair specific clinical skillsets with specific industry initiatives.

EXCHANGE YOUR EXPERTISE

Learn how you can unlock the power of your expertise and experience to impact the healthcare industry in ways never before imagined

REGISTER NOWLEARN MORE

EXTEND, EXCEL…EXPLORE THE EXCHANGE

Learn how you can cost-effectively multiply your sales, education and R&D resources in an instant

REGISTER NOWLEARN MORE

COMMUNITY PORTAL

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

My Patient May Have a Mitochondrial Disease: What Should I Do?

Published: Fri, 17 Aug 2018 10:28:56 EDT
All patients with a suspected mitochondrial disease should be seen by a mitochondrial medicine expert. But what can the primary care clinician do while waiting for that to happen?
CHOP Expert Commentary

In HIV, Viral Load Matters and PrEP Is Still Critical

Published: Fri, 17 Aug 2018 10:10:46 EDT
Some good news for HIV patients with a suppressed viral load.
Medscape Internal Medicine

Biologic Agents Are Changing the Landscape of Severe Asthma

Published: Fri, 17 Aug 2018 10:01:00 EDT
A fourth biologic for severe eosinophilic asthma may soon be available. Who is a candidate for this therapy and what effects can you expect?
Medscape Pulmonary Medicine
Displaying results 13-15 (of 20)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

HEALTHCARE SUPPLIER NEWS

Andrew Cheng to quit Gilead 6 months after taking CMO post

Published: Wed, 15 Aug 2018 09:11:59 +0000
Andrew Cheng is set to leave Gilead six months after being appointed CMO. Cheng’s swift exit keeps the revolving door spinning at the top of Gilead, which is set to lose its CEO, CMO, CSO and executive chairman over a nine-month window.

How elephants resist cancer by reviving a ‘zombie’ gene

Published: Tue, 14 Aug 2018 17:09:55 +0000
Researchers at the University of Chicago have discovered that in elephants, the tumor-suppressor gene p53 awakens a dormant gene, which goes on to kill cancer precursor cells. They believe the discovery could be used to develop drugs that mimic this process.

Insilico, Juvenescence and the Buck Institute form AI-based venture to tackle metabolism and aging-related diseases

Published: Tue, 14 Aug 2018 13:48:18 +0000
A triumvirate of aging-focused biotechs and researchers—the AI company Insilico Medicine, the portfolio-based startup Juvenescence and the nonprofit Buck Institute—have formed a new joint venture to develop small molecules for a novel target in a bid to extend life spans.
Displaying results 13-15 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 

HAVE A QUESTION?

 Security code
1-800-4-the-clinx

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top